FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO (cemiplimab), in patients with solid tumors. This partnership marks a significant step in cancer research, potentially leading to more effective treatments for patients suffering […]
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and metabolic diseases, autoimmune disorders, ophthalmology, and other major diseases, has announced the presentation of preclinical data on multiple novel bispecific antibodies and antibody-drug conjugates (ADCs) from its oncology pipeline at […]
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies, has made a groundbreaking announcement. The U.S. Food and Drug Administration (FDA) has approved AMTAGVI (lifileucel) suspension for intravenous infusion, marking a significant milestone in the treatment of adult patients with unresectable […]
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review of their recent application. This significant step involves a Type II variation application for PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab), targeting first-line treatment of adult patients with previously untreated […]
Iksuda Therapeutics, a clinical-stage biotechnology firm from the UK specializing in innovative antibody drug conjugates (ADCs) for tumor specificity, reported successful completion of the first therapy cycle for IKS014. This ADC, targeting advanced HER2+ solid tumours, moves ahead following encouraging results from Phase 1 trials managed by Fosun Pharma. Fosun’s efforts have initiated further trials […]
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 “ELUCIDATE” study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 (‘617), in the treatment of advanced solid tumours. The trial aims to investigate the safety, efficacy, and pharmacokinetics of GTAEXS617 through multiple ascending doses for patients with advanced solid tumours, including […]
Biomea Fusion is all set to take BMF-219 into clinical trials in patients having unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC) with an activating KRAS mutation. The upcoming milestone for the NASDAQ-listed biopharma company follows the clearance of the US Food and Drug Administration […]
Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. IK-930 is a TEAD inhibitor designed to target the Hippo signaling pathway. Earlier this year, IK-930 was granted the FDA orphan drug designation for the treatment of patients having malignant […]
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the Nasdaq, Turning Point Therapeutics is developing drug candidates that are said to target the highly common mutations related to oncogenesis. Its flagship asset is repotrectinib, which is a tyrosine kinase […]
Alphamab Oncology said that it has completed enrolling patients in China for its KN026-203 phase 2 clinical trial of the combination of KN026 and KN046 in the treatment of HER2-positive solid tumors. While KN026 is a HER2 bispecific antibody developed by the Chinese clinical-stage biopharma company, KN046 is a PD-L1/CTLA-4 bispecific antibody, developed by Jiangsu […]
